Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 2AM EDT 5 min · 24 Sep 2026 · NPR News Now

Entertainment Catch-Up: Presley Gerber, Phones in Theatres and Channing Tatum's Troll Account(?) 39 min · 24 Sep 2026 · Catch Up with Louise McSharry

2AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

How To Naturally Lift & Sculpt Your Face, Define Your Jawline & Age Better Without Injectables 1h 3m · 24 Sep 2026 · The Bossticks

Cómo dejar ir a alguien que todavía amas | Jueves de Lety & Ash | Episodio 697 22 min · 24 Sep 2026 · Se Regalan Dudas

Dead Internet 2026: DARPA, Peter Thiel, Alien AI & Memetic Magick 1h 47m · 24 Sep 2026 · Occult Symbolism and Pop Culture with Isaac Weishaupt

Report any issue

Source

Recorded23 Sep 2021

Publisherfeeds.transistor.fm ↗

Handlerec:11742121

Show notes

In this week’s episode, we review results of preclinical investigations that sound a note of caution regarding the potential use of JAK inhibitors as treatment for hemophagocytic lymphohistiocytosis (or HLH), research that provides new insights on how CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax, and conclude with a report that demonstrates cooperation between B cell receptor signaling and genetic lesions in CDKN2A, CDKN2B and TP53 in Richter transformation.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in